Scientists have identified two specific types of brain cells that behave differently in people with depression, offering a ...

Motif’s study primarily aims to validate the safety of its XCS system over a 12-month period following implantation.

Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced the initiation of a Phase 2b randomized, ...

On Tuesday, Alto Neuroscience, Inc. (NASDAQ:ANRO) announced an asset purchase agreement with Chase Therapeutics Corporation for a portfolio of dopamine agonist drug combinations for ...

An AI-based machine learning tool identified depression in 71% of people with the condition from under a minute of free speech. The findings may enable more widespread screening for the condition. The ...

Alto Neuroscience Inc. (NYSE:ANRO) is one of the best IPO stocks to buy according to Wall Street analysts. On June 26, Alto Neuroscience announced positive pharmacodynamic results from an exploratory ...

A new study reveals how chronic pain triggers depression through structural changes in the brain's hippocampus.

Rates of depression and stress-related disorders rise among new fathers a year after birth, even though they have fewer mental health diagnoses during pregnancy and the first few months after birth.

AbbVie ABBV is set to report first-quarter 2026 results on April 29. While the company’s immunology portfolio will remain the primary focus, its neuroscience segment is expected to contribute ...